He Dou
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 10%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Breast Cancer Treatment Studies 2
- Protease and Inhibitor Mechanisms 1
- Oncology 3
- Inflammatory Biomarkers in Disease Prognosis 1
- Cancer Risks and Factors 1
- Peptidase Inhibition and Analysis 1
- Co-authors
- Min Xiao (10 shared papers)Shanshan Yang (2 shared papers)Yingpu Li (1 shared paper)Yu Xi (1 shared paper)Zhiren Zhang (1 shared paper)Zhennan Yuan (1 shared paper)Xueying Wang (1 shared paper)Sifan Zhang (1 shared paper)
- Journals
- Frontiers in Oncology (2 papers)Molecular Cancer (1 paper)Diagnostic Pathology (1 paper)BMC Women s Health (1 paper)Experimental Cell Research (1 paper)
- Partner nations
- China
In The Last Decade
He Dou
8 papers receiving 749 citations
He Dou's Hit Papers
Peers
Comparison fields: 5 of 82
- Cancer Research 190
- Oncology 204
- Immunology and Allergy 39
- Immunology 128
- Cell Biology 73
Countries citing papers authored by He Dou
This map shows the geographic impact of He Dou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by He Dou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites He Dou more than expected).
Fields of papers citing papers by He Dou
This network shows the impact of papers produced by He Dou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by He Dou. The network helps show where He Dou may publish in the future.
Co-authors
The 21 scholars most cited alongside He Dou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments Hit paper breakdown → | 2023 | 567 |
| 2 | 2020 | 136 | |
| 3 | 2023 | 21 | |
| 4 | 2024 | 13 | |
| 5 | 2024 | 6 | |
| 6 | 2023 | 3 | |
| 7 | 2025 | 2 | |
| 8 | 2025 | 1 | |
| 9 | 2023 | 0 | |
| 10 | 2024 | 0 |
About He Dou
He Dou is a scholar working on Cancer Research, Oncology, Molecular Biology, Immunology and Allergy and Immunology, having authored 10 papers that have together received 749 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (2 papers), Cell Adhesion Molecules Research (1 paper), Inflammatory Biomarkers in Disease Prognosis (1 paper), Protease and Inhibitor Mechanisms (1 paper), Cancer Risks and Factors (1 paper), Cell death mechanisms and regulation (1 paper), Peptidase Inhibition and Analysis (1 paper) and Inflammasome and immune disorders (1 paper). The work is most often cited by research in Cancer Research (190 citations), Oncology (204 citations), Immunology and Allergy (39 citations), Immunology (128 citations) and Cell Biology (73 citations). He Dou has collaborated with scholars based in China. Frequent co-authors include Min Xiao, Shanshan Yang, Yingpu Li, Yu Xi, Zhiren Zhang, Zhennan Yuan, Xueying Wang, Sifan Zhang, Shuang Ma and Feng Liu. Their work appears in journals such as Frontiers in Oncology, Molecular Cancer, Diagnostic Pathology, BMC Women s Health and Experimental Cell Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.